Project Grant R21AI185519

Award Date 1/15/25
Completion Date 12/31/26
Dollars Obligated $231K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award of $438,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at the University of California, San Diego (UCSD) to investigate the mechanisms regulating immunoglobulin gene rearrangement. The research aims to determine how enhancers and epigenetic modifications orchestrate chromatin dynamics and spatial confinement to enrich interactions between variable...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $385,575 to the University of California, San Diego (UCSD) to conduct research on the genetic and immunological mechanisms underlying a severe childhood autoimmune disorder known as disabling pansclerotic morphea (DPM). The key objectives of this 5-year project are to: 1) determine how a gain-of-function mutation in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,580,712 to Harvard Medical School to conduct research on the gut complement system and its role in protecting against enteric infections. The research, led by Harvard's Dr. Meng Wu, has three key objectives: Determine the specific intestinal cell types responsible for producing complement component C3, which is critical for combating enteric...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $142,908 to the San Diego Biomedical Research Institute to conduct research on how antibody glycosylation influences natural killer (NK) cell activation and antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The key objectives are to: 1) Determine how monoclonal antibody glycosylation profiles affect signaling protein...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $192,788 to the University of California, San Diego to conduct a genome-wide screening and analysis of regulators of plasmacytoid dendritic cell (pDC) function and exhaustion. The research aims to gain a comprehensive understanding of the mechanisms that control interferon-I production and exhaustion in pDCs, which are critical innate immune...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $563,500.00 to develop and characterize novel complement inhibitors for treating complement-mediated hematologic diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). The award supports a two-phase research project to first develop additional novel complement inhibitors and thoroughly...
This $793,093 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the regulatory landscape of systemic lupus erythematosus (SLE) and its cardiovascular disease (CVD) comorbidity. The grantee, Oklahoma Medical Research Foundation, will conduct systematic, high-throughput studies in macrophages derived from induced pluripotent stem cells to identify genetic variants that disrupt regulatory...
The federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $972,151 to The Regents of the University of California, San Francisco (UCSF) to conduct systematic genetic investigations of the mechanisms governing immunogenic cell death (ICD). The project aims to enhance understanding of the molecular signals and cellular processes that determine whether phagocytes...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,194,992 to the University of California, San Diego (UC San Diego) to conduct research on the roles and regulation of tissue-resident CD8 T cells during a persistent viral infection. The key objectives are to: (1) evaluate the role of tissue-resident CD8 T cells in intestinal hyper-permeability and colitis during a sustained viral...
This Project Grant award of $856,202 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), which oversees the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award will fund a 5-year study led by researchers at the University of California, San Francisco (UCSF) to investigate the role of IL-10 and IFN signaling in controlling the HIV reservoir and achieving functional HIV cure. The project aims to determine if enhancing IL-10 and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $231,345 to the University of California, San Diego (UCSD) to conduct research on the role of heparan sulfate in regulating the complement system and its potential impact on complement-mediated diseases. The key objectives of this 2-year project are to: (1) define the binding interactions between complement regulatory proteins (Factor H and Factor H-related proteins) and heparan sulfate using in vitro models; (2) examine the impact of heparan sulfate on complement activation in a mouse model of Factor H deficiency; and (3) evaluate the therapeutic potential of heparan sulfate oligosaccharides for modulating tissue-specific complement regulation. This research aims to improve the scientific understanding of how the diverse heparan sulfate landscape influences the regulation of the complement system, which could lead to new therapeutic approaches for complement-driven diseases.

Generated 8/5/25, 3:48 AM